###begin article-title 0
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 47 49 47 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 58 60 58 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
Whether cancer stem cells occur in BRCA1-associated breast cancer and contribute to therapeutic response is not known.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 64 79 64 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1deficient </italic>
###xml 79 84 <span type="species:ncbi:10090">mouse</span>
We generated and characterized 16 cell lines from five distinct Brca1deficient mouse mammary tumors with respect to their cancer stem cell characteristics.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 78 80 78 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 233 234 233 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 239 241 239 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 282 284 282 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 650 651 650 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 656 658 656 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 666 668 666 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 760 761 760 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 766 768 766 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 776 778 776 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1055 1059 1055 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Oct4</italic>
###xml 1061 1067 1061 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch1</italic>
###xml 1069 1074 1069 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aldh1</italic>
###xml 1076 1081 1076 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr1</italic>
###xml 1087 1091 1087 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox1</italic>
###xml 1114 1115 1114 1115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1120 1122 1120 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1131 1133 1131 1133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 123 128 <span type="species:ncbi:9606">human</span>
###xml 356 361 <span type="species:ncbi:9606">human</span>
###xml 366 372 <span type="species:ncbi:10090">murine</span>
###xml 866 870 <span type="species:ncbi:10090">mice</span>
All cell lines derived from one tumor included increased numbers of CD44+/CD24- cells, which were previously identified as human breast cancer stem cells. All cell lines derived from another mammary tumor exhibited low levels of CD44+/CD24- cells, but they harbored 2% to 5.9% CD133+ cells, which were previously associated with cancer stem cells in other human and murine tumors. When plated in the absence of attachment without presorting, only those cell lines that were enriched in either stem cell marker formed spheroids, which were further enriched in cells expressing the respective cancer stem cell marker. In contrast, cells sorted for CD44+/CD24- or CD133+ markers lost their stem cell phenotype when cultured in monolayers. As few as 50 to 100 CD44+/CD24- or CD133+ sorted cells rapidly formed tumors in nonobese diabetic/severe combined immunodeficient mice, whereas 50-fold to 100-fold higher numbers of parental or stem cell depleted cells were required to form few, slow-growing tumors. Expression of stem cell associated genes, including Oct4, Notch1, Aldh1, Fgfr1, and Sox1, was increased in CD44+/CD24- and CD133+ cells. In addition, cells sorted for cancer stem cell markers and spheroid-forming cells were significantly more resistant to DNA-damaging drugs than were parental or stem cell depleted populations, and they were sensitized to the drugs by the heat shock protein-90 inhibitor 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 102 104 102 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 16 21 <span type="species:ncbi:10090">mouse</span>
###xml 154 159 <span type="species:ncbi:9606">human</span>
Brca1-deficient mouse mammary tumors harbor heterogeneous cancer stem cell populations, and CD44+/CD24- cells represent a population that correlates with human breast cancer stem cells.
###end p 9
###begin p 10
See related editorial by Wicha,
###end p 10
###begin title 11
Introduction
###end title 11
###begin p 12
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 298 304 298 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 487 488 487 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 512 518 512 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 797 803 797 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 852 853 852 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 854 855 854 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 909 915 909 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
BRCA1 was the first identified breast cancer susceptibility gene and was localized to 17q21 by positional cloning more than 15 years ago [1]. BRCA1 is mutated in about 2.5% to 5% of all breast cancers, in 45% of inherited breast cancer families, and in up to 80% of breast/ovarian cancer families. BRCA1 mutation is associated with a high incidence of bilateral disease, and confers an 82% risk for developing breast cancer and an 54% risk for developing ovarian cancer by age 80 years [2]. Somatic mutations of BRCA1 have been reported in up to 10% of cases of sporadic ovarian cancer, but they are extremely rare in sporadic breast cancer [3-5]. However, reduced BRCA1 protein expression is detected in high-grade sporadic breast and ovarian tumors, suggesting that epigenetic downregulation of BRCA1 contributes to their aggressive clinical course [6-8]. The existence of cancer stem cells associated with BRCA1 mutations or downregulation has not been reported.
###end p 12
###begin p 13
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 461 462 461 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 466 472 466 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 888 890 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 944 949 944 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 425 430 <span type="species:ncbi:9606">human</span>
###xml 634 638 <span type="species:ncbi:10090">mice</span>
###xml 712 717 <span type="species:ncbi:10090">mouse</span>
###xml 748 773 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 775 779 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 794 798 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
In spite of early detection and aggressive surgical and chemotherapeutic approaches, no significant 5-year survival benefits have been achieved in patients harboring BRCA1 mutations [6]. During the past several years, cancer stem cells have been subjected to increasing scrutiny as a potential cause of relapse and drug resistance [9]. Several groups [10,11] identified a small subpopulation of highly tumorigenic cells from human breast tumors bearing the CD44+CD24-/low lineage phenotype, which have drug-resistant phenotype and the capacity to form tumors after transplantation in nonobese diabetic/severe combined immunodeficient mice. Subsequent enrichment in Sca-1 positive cancer stem cells was shown for mouse mammary tumor models, such as mouse mammary tumor virus (MMTV)-Her2/neu and MMTV-Wnt1 [12], and Thy1/CD24 expression further defined cancer stem cells in the Wnt1 model [13]. No studies have yet been conducted to characterize Brca1-deficient cancer stem cells.
###end p 13
###begin p 14
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 187 192 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 197 201 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">exon</italic>
###xml 192 204 192 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#916;<italic>exon</italic>11 </sup>
###xml 215 218 211 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 218 222 214 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 324 326 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 342 348 338 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 633 638 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 638 649 634 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#916;exon11</sup>
###xml 650 653 642 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 653 657 645 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 9 14 <span type="species:ncbi:10090">mouse</span>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 358 363 <span type="species:ncbi:10090">mouse</span>
Multiple mouse models with targeted deletion of Brca1 in the mammary gland generate tumors with low penetrance [14]. Increased incidence of these tumors is observed in mice harboring two Brca1Deltaexon11 genes in a p53+/- background, with uniform deletion of p53 in these tumors. Lymphomas were also reported in this model [15]. However, the Brca1 deficient mouse mammary tumors have variable penetrance and latency, which makes it nearly impossible to use these models to standardize therapies and to study the stem cell population. To overcome these difficulties, we developed and characterized 16 cell lines from five independent Brca1Deltaexon11/p53+/- tumors. We examined these cell lines for specific cell populations using multiple known stem cell markers. Cell populations expressing putative stem cell markers were more resistant to chemotherapeutic agents than were parental cells, and had other characteristics of cancer stem cells, including reconstitution of tumors by as few as 50 to 100 cells.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
Generation of cell lines from Brca1 mouse mammary tumors
###end title 16
###begin p 17
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 100 107 100 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#916;11</sup>
###xml 107 110 103 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 110 114 106 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 167 168 163 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 586 592 <span type="species:ncbi:9913">bovine</span>
Brca1 tumor cell suspensions were prepared as described by Varticovski and coworkers [16] from Brca1Delta11p53+/- mammary tumors. Briefly, mice were euthanized with CO2, and tumors were collected aseptically and mechanically dissociated. Cells were passaged through a 40 mum mesh screen, and were further dissociated by serial passage through a syringe with 18 to 25 gauge needles. Cells were plated at low density for selection of individual clones. Cells were grown at 37degreesC in 5% carbon dioxide in RPMI 1640 media supplemented with penicillin/streptomycin, glutamine, and fetal bovine serum starting with 2% and progressively increasing to 10%. More than 40 clones were isolated using cloning cylinders and a total of 16 cell lines were developed from five independent primary tumors. Each cell line was passaged weekly and maintained in culture for up to 50 passages.
###end p 17
###begin title 18
Characterization of unsorted cells that survive in long-term cultures in the absence of attachment
###end title 18
###begin p 19
The ability of cells to grow in the absence of attachment was tested by plating cells on low-binding plates (Fisher Scientific, Hampton, NH, USA). Under these conditions, some cell lines showed surviving floating colonies that formed compact spheroids after 3 to 4 weeks of culture. Spheroid formation frequency for each cell line was tested by plating cells in limiting dilution from 500 to 1 cell/well on 96-well low-binding plates in sextuplicate. The number of colonies was scored weekly, and the spheroids were dispersed into single cells and upstaged to six-well plates after 3 weeks. To obtain single cell suspension, spheroids were collected and washed in phosphate-buffered saline (PBS). Single cell suspension was obtained by incubation in collagenase/dispase and DNAse (Roche, Switzerland), filtering through a 40 mum filter to remove remaining aggregates (Fisher Scientific), and plated directly onto 96-well tissue culture plates for drug testing or passaged onto a new low-binding plate for expansion.
###end p 19
###begin title 20
Analysis of cell surface markers
###end title 20
###begin p 21
###xml 172 178 <span type="species:ncbi:9913">bovine</span>
###xml 218 223 <span type="species:ncbi:10090">mouse</span>
###xml 277 282 <span type="species:ncbi:10090">mouse</span>
###xml 331 336 <span type="species:ncbi:10090">mouse</span>
###xml 394 399 <span type="species:ncbi:10090">mouse</span>
###xml 452 455 <span type="species:ncbi:10116">Rat</span>
Cell lines grown as monolayer were trypsinized, and cells grown as spheroids were dispersed to obtained single cell populations, as above. Cells were washed in PBS with 1% bovine serum albumin and stained with PE anti-mouse CD24 (BD Pharmingen, San Jose, CA, USA), or APC anti-mouse CD24 (Biolegend, San Diego, CA, USA), FITC anti-mouse CD44 (Southern Biotech, Birmingham, AL, USA), or PE anti-mouse prominin-I CD133 (eBioscience, San Diego, CA, USA). Rat IgG (CHEMICON, Billerica, MA, USA) was used as the isotype control, in accordance with the manufacturer's instructions. Cells were analyzed by flow cytometry using LSR II (BD Biosciences, San Jose, CA, USA). Data were collected using FACSDiVa software (BD Biosciences) from no fewer than 30,000 cells.
###end p 21
###begin title 22
Cytotoxicity assay and calculation of combination index
###end title 22
###begin p 23
Doxorubicin was obtained from Sigma (St. Louis, MO, USA) and dissolved in PBS as 10 mmol/l stock. Aliquots were frozen and diluted in media immediately before use. Cisplatin and etoposide were obtained from Sigma-Aldrich (St. Louis, MO, USA). 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride) was obtained from Invivogen (San Diego, CA, USA). These drugs were dissolved in dimethyl sulfoxide, stored as 10 mmol/l stock aliquots, and diluted in media immediately before use.
###end p 23
###begin p 24
###xml 878 879 877 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1463 1465 1455 1457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
Cells were seeded in six replicates in 96-well plates at 10,000 cells per well. Serial dilutions of doxorubicin, cisplatin, etoposide, and 17-DMAG in medium were added to the cells on the following day or as indicated. Dose-response curves to single drugs at 24 hours, 48 hours, and 72 hours after exposure were generated to determine the range of concentrations to be used in combination. For drug interaction studies, drugs were added sequentially (with the 17-DMAG introduced with a 24-hour delay) or simultaneously in a final volume of 100 mul. Cytotoxicity was measured using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA), which is a colorimetric method for determining the number of viable cells based on bioreduction of the tetrazolium compound MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) by metabolically active cells. After exposure to a single drug or after a total of 48 hours in sequential addition experiments, 20 mul MTS reagent was added to each well and the plates were incubated in a humidified 37degreesC incubator with 5% carbon dixoide for 1 to 4 hours. Absorbance at 490 nm was recorded using a 96-well plate reader. Data were averaged and normalized against the average survivals of untreated samples and analyzed using CalcuSyn (Biosoft, Ferguson, MO, USA), software based on the multiple drug-effect equation of Chou and Talalay [17].
###end p 24
###begin title 25
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Tumor growth in vivo
###end title 25
###begin p 26
###xml 788 790 787 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 791 793 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 389 394 <span type="species:ncbi:10090">mouse</span>
###xml 489 493 <span type="species:ncbi:10090">mice</span>
All studies were conducted in an AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International) accredited facility, in compliance with the US Public Health Service guidelines for the care and use of animals in research. Parental cells and cells sorted for indicated cell surface markers were resuspended in 100 mul RPMI media and injected into the inguinal mouse fat pad (pad #4) of 6- to 8-week-old female nonobese diabetic/severe combined immunodeficient mice. The growth of tumors was monitored using caliper measurements to determine tumor mass. Weights (milligrams) were calculated from measurements (millimeters) of two perpendicular dimensions (length and width) using the formula for a prolate ellipsoid and assuming a specific gravity of 1.0 mg/mm3 [18].
###end p 26
###begin title 27
RNA extraction and analysis of stem cell-associated genes
###end title 27
###begin p 28
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), in accordance with the manufacturer's instructions, followed by DNAse treatment and RNA clean-up (RNeasy Mini Kit; Qiagen, Valencia, CA, USA). RNA concentration and integrity was determined using the RNA 6000 Nano LabChip Kit (Qiagen) on Agilent 2100 Bioanalyzer.
###end p 28
###begin p 29
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 82 87 <span type="species:ncbi:9606">human</span>
The mRNA levels of 84 genes associated with stem cell biology were examined using human Stem Cell RT2 profiler arrays (SuperArray Bioscience, Frederick, MD, USA), in accordance with the manufacturer's instructions. RNA (250 to 500 ng) was reverse transcribed using the First Strand Synthesis Kit (Qiagen), and cDNA was subjected to real-time PCR using SYBR green/ROX Master Mix (Qiagen) and PCR cycles were performed on a 7500 Real Time PCR System (Applied Biosystems, Foster City, CA, USA). A dissociation curve was run as a quality control using default melting curve settings. Values obtained for the threshold cycle for each gene were normalized using the average of housekeeping genes amplified on the same array.
###end p 29
###begin title 30
Real-time quantitative RT-PCR
###end title 30
###begin p 31
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 893 899 893 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pmca4 </italic>
###xml 935 937 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
Real-time quantitative RT-PCR was used to measure mRNA expression levels of selected mouse ATP-binding cassette (ABC) transporters using LightCycler RNA Master SYBR Green Kit and the LightCycler 480 instrument (Roche Biochemicals, Indianapolis, IN, USA). Specific PCR primer sequences for genes are listed in Additional file 1. All RT-PCR reactions were performed on 200 to 400 ng total RNA with 250 nmol/l specific primers. Negative controls consisting of no-template (water) reaction mixtures were run with all reactions. Melting curves were determined for each primer set following all RT-PCR runs using the LightCycler 480 software. Crossing points for each transcript were determined using the second derivative maximum analysis with the arithmetic baseline adjustment. Crossing point values for each transporter were normalized to the respective crossing point values for reference gene Pmca4 (plasma membrane calcium ATPase 4) [19]. Data are presented as fold change in gene expression using the DeltaDeltaCt method.
###end p 31
###begin title 32
Immunostaining
###end title 32
###begin p 33
###xml 299 305 <span type="species:ncbi:9793">donkey</span>
Cells growing as spheroids were expanded in low-binding six-well plates, collected, allowed to attach over 2 hours to a multiwell chamber coated with D-poly L-lysine, fixed in 4% paraformaldehyde, and permeabilized with 0.3% Triton X-100 in PBS (15 minutes) and washed in PBS. Cells were blocked in donkey serum for 1 hour, and incubated with anti-Numb, anti-Oct4, anti-Nestin, or anti-CD133 primary antibodies overnight (Abcam, Cambridge, MA, USA). Secondary antibodies conjugated to Alexa Fluor 488 and Alexa Fluor 568 (Molecular Probes, Eugene, OR, USA) were added for 1 hour, washed in PBS, and mounted under a coverslip using Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA, USA). Immunofluorescence was visualized in an Olympus 1X51 fluorescence microscope (Olympus America Inc., Center Valley, PA, USA.
###end p 33
###begin title 34
Results
###end title 34
###begin title 35
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
Characterization of cell lines from Brca1 mouse mammary tumors
###end title 35
###begin p 36
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 70 81 70 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#916;exon11</sup>
###xml 82 85 78 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 85 89 81 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 111 113 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 114 116 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 312 313 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 344 350 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 372 374 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 429 434 425 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 434 446 430 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#916;exon11 </sup>
###xml 457 460 449 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 89 94 <span type="species:ncbi:10090">mouse</span>
Sixteen cell lines were generated from five independent original Brca1Deltaexon11/p53+/- mouse mammary tumors [15,16]. These cells had similar doubling time of approximately 18 to 20 hours and similar morphology with epithelioid appearance, although A1-derived cell lines had some rounded cells (Additional file 2). As previously described for Brca1 tumors in this model [15], all original tumors and cell lines expressed mutant Brca1Deltaexon11 and lacked p53, as determined by PCR (data not shown). Several cell lines representing each one of the five original tumors were selected at random for additional studies.
###end p 36
###begin p 37
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 218 224 218 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 560 561 560 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 566 568 566 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 613 618 <span type="species:ncbi:9606">human</span>
To determine whether Brca1 cell lines contain a distinct population of cancer stem cells, we examined expression of cell surface markers previously assigned to human breast cancer stem cells, namely CD44 and CD24. All Brca1 clones expressed CD44 to varying degrees, with the B.15 cell line expressing the lowest percentage of positive cells (Figure 1a). Expression of CD24 was also similar among the cell lines, but higher in B.15 cells (Figure 1b). All cell lines derived from A1 tumor (A1.1, A1.8, and A1.10) exhibited a higher (1.32% to 5%) fraction of CD44+/CD24- cells, which correlate with the phenotype of human breast cancer stem cells (Figure 1d).
###end p 37
###begin p 38
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 95 99 95 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 350 354 350 354 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 420 424 420 424 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 465 467 465 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 537 541 537 541 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 717 718 717 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 723 725 723 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
Expression of putative stem cell markers from cells derived from five individual Brca1 tumors. (a) Cell surface expression of CD44 is relatively uniform across all cell lines. The open histograms, outlined by a black line, represent positive staining for CD44, and gray filled histograms show negative controls stained with matched isotype antibody. (b) Expression of CD24 is variable, with highest level in B.15 cells. (c) There was substantial expression of CD133+ cells, accounting for 5.9% of the total population, among RP.1 cells. (d) Co-expression of CD44 and CD24 markers. The quadrants are gated to separate double positive, single positive, and double negative populations. The percentage of cells with CD44+/CD24- markers is indicated at the upper left of each panel. The highest fraction is in cells derived from A1 tumor, as represented by A1.8 cells. One of more than three independent experiments is shown here.
###end p 38
###begin p 39
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 228 230 228 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 351 353 351 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 399 401 399 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 409 410 409 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 415 417 415 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 542 547 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 558 563 <span type="species:ncbi:10090">mouse</span>
We also tested whether Brca1 cells express CD133, a marker not previously described in association with breast cancer, but shown to mark cancer stem cells in other tumors. Only RP tumor-derived cell lines had a significant CD133+ population, which varied between 2% and 5.9%, as shown for RP.1 cell line (Figure 1c). All other cell lines had low CD133+ population. There was no overlap between CD133+ and CD44+/CD24- populations, as determined by analysis of cells after triple staining (Additional file 3 [panels A and B]). Thus, individual Brca1-deficient mouse mammary tumors gave rise to cell lines with distinct populations of cells expressing stem cell markers. The studies described below address differences and similarities between these putative cancer stem cell populations, as defined by these two types of cell surface markers.
###end p 39
###begin title 40
Cells that express stem cell markers survive and proliferate as spheroids in long-term cultures in the absence of attachment
###end title 40
###begin p 41
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 318 319 318 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 324 326 324 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 335 336 335 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 346 347 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 352 354 352 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 357 358 357 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 638 640 638 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 749 751 749 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 905 913 905 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1296 1304 1296 1304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
A characteristic of cancer stem cells is their ability to grow in three-dimensional structures in semisolid support or in liquid culture in the absence of attachment, termed spheroids or mammospheres. To determine the capacity of Brca1 cells to form spheroids in the absence of attachment, we sorted A.8 cells for CD44+/CD24- cells (SC+) and CD44-/CD24+ (SC-) populations. Cells were plated by limiting dilution from 500 to 1 cell/well in six replicate wells in low-binding 96-well plates. Over 2 to 3 weeks, some cells and cell aggregates were formed but degenerated, but many survived and formed tight actively growing spheroids. The SC+ population exhibited a significantly higher number of proliferating viable spheroids, as compared with the SC- population, and generated spheroids even when plated as a low as four to six cells/well (Figure 2a). To determine whether these spheroids can be expanded in vitro, the spheroids were dissociated into single cell suspensions and passaged multiple times in long-term sphere-forming assay. These cells repeatedly formed spheroids for up to eight subsequent passages when plated in the absence of attachment. Thus, the A1.8 cell line contains a population of cells that survives in the absence of attachment and forms spheroids that can be expanded in vitro.
###end p 41
###begin p 42
###xml 104 108 104 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 186 188 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 193 194 193 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 199 200 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 221 223 221 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 234 235 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 394 395 394 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 400 402 400 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 466 467 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 472 474 472 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 675 679 673 677 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 688 694 686 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 1367 1368 1365 1366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1373 1375 1371 1373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1469 1473 1467 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Low </italic>
###xml 1467 1473 1465 1471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/<italic>Low </italic></sup>
Cells that express stem cell markers survive and form spheroid structures in the absence of attachment. (a) Frequency of spheroid formation is increased in Brca1 A1.8 cells sorted for SC+ (CD44+/CD24-) as compared with SC- (CD24+/CD44-) populations. The results shown are from long-term spheroid assay performed by limiting dilution. The black bars represent numbers of spheroids formed by CD44+/CD24- sorted cells/well and the white bars represent numbers from CD24+/CD44- cells +/- standard deviation from six replicate wells at the end of 2 weeks in culture. The numbers on the ordinate show the number of cells plated/well. One of three independent experiments is shown. (b) Unsorted Brca1 A1.8 cells plated in the absence of attachment form spheroids, which are enriched in cells expressing stem cell markers. A1.8 were plated as single cells in low binding plates for 2 to 3 weeks, and the resulting spheroids were expanded for 4 subsequent passages, dispersed into single cell population, and stained with appropriate antibodies (as described in Materials and methods). The CD44 and CD24 markers are shown as an open histogram on the left, and filled histograms show negative controls stained with matched isotype antibody. The single stain analysis is on the right panel; the double staining is shown on the bottom. Results are presented as percentage of CD44+/CD24- cells from the total population. Note the appearance of a dual population that contains CD24-/Low cells not evident in parental cells run side-by-side with the spheroid-derived cells and illustrated for the parental A1.8 cell line in Figure 1. One representative experiment from more than three is shown here.
###end p 42
###begin title 43
Spheroids formed from unsorted cells are enriched in cells which express cancer stem cell markers
###end title 43
###begin p 44
###xml 696 702 696 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 901 902 901 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 907 909 907 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 971 972 971 972 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 977 982 977 982 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low</sup>
###xml 1065 1067 1065 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1114 1115 1114 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
To determine the expression of putative cancer stem cell markers in the spheroids, we plated A1.8 and RP.1 cell lines without prior sorting as single cells/well in low-binding 96-well plates. The frequency of spheroid formation was 2% to 4%, as expected from the fraction of cells expressing respective cancer stem cell markers in these cell lines. The resulting spheroids were dissociated into single cells and expanded in 96-well and then in six-well low-binding plates. Analysis of cells derived from spheroids after multiple passages showed spontaneous enrichment in cells expressing putative cancer stem cell markers. In addition, a distinct subpopulation of cells was evident, namely a CD24-/low population (Figure 2b), which was not previously observed in any of the parental cell lines (Figure 1b and data not shown). More than 10% of cells derived from expanded A1.8 spheroids acquired a CD44+/CD24- phenotype (Figure 2b, lower panel) and more than 30% were CD44+/CD24-/low. Similar observations were made for RP.1 cells, in which spheroids had 27.7% CD133+ cells after multiple passages (Additional file 4).
###end p 44
###begin p 45
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 449 450 449 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 719 727 719 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 809 810 809 810 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 815 817 815 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 825 827 825 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 989 990 989 990 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 995 997 995 997 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
To determine whether any of the other Brca1 cell lines can grow in the absence of attachment, we plated each of the 16 cell lines in long-term spheroid-forming assay in limiting dilution, and as single cells/well. Cells were monitored for growth and the number of spheroids was scored after 2 to 3 weeks in culture. Cell morphology varied greatly, as shown for A1.1, A1.8, B.15, P3.17, P2.1, and RP.1 cells after 2 weeks in culture (Additional file 5). Cell lines derived from B, P2, and P3 tumors had small aggregates and floating nonviable cells. In contrast, all cell lines from A1 and RP.1 tumors had viable spheroids in 96-well cultures, and proliferated vigorously as spheroids after subsequent multiple passages in vitro. Coincidently, these cell lines also exhibited a higher fraction of cells in CD44+/CD24- or CD133+ populations, respectively. Because other cell lines failed to grow as spheroids, we did not attempt to characterize the minute fraction of cells that express CD44+/CD24- markers in those cell lines.
###end p 45
###begin title 46
Cells sorted for putative stem cell markers repopulate the parental cell fractions after few passages in monolayer culture
###end title 46
###begin p 47
###xml 236 237 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 242 244 242 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 247 248 247 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 257 258 257 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 263 265 263 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 268 269 268 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 323 325 323 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 344 345 344 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 350 352 350 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S6">6</xref>
###xml 493 494 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 558 559 558 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 564 566 564 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 608 609 608 609 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 614 616 614 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 656 657 656 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 662 664 662 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 719 720 719 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 725 727 725 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 735 736 735 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 741 743 741 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 813 814 813 814 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 819 821 819 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 861 862 861 862 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 867 869 867 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
We examined whether cells sorted for positive or negative expression, or whether the putative stem cell makers maintain their phenotypes when grown as monolayers in conventional tissue culture dishes. A1.8 cells were sorted as 100% CD44+/CD24- (SC+) or CD44-/CD24+ (SC-) populations and plated as monolayer. Only 2.7% of SC+ cells retained CD44+/CD24- phenotype after three passages, thus reconstituting the 1.32% to 5% fraction found in parental cells (Additional file 6 [panel A] and Figure 1). Furthermore, cells sorted from the opposite quadrant for CD44-/CD24+ phenotype continued to be depleted in CD44+/CD24- markers (0.05%). Thus, expansion of CD44+/CD24- cells in monolayer leads to reconstitution of both CD44+/CD24- and CD44-/CD24+ cell fractions found in parental cells, whereas cells depleted of CD44+/CD24- cells were unable to repopulate the CD44+/CD24- fraction.
###end p 47
###begin p 48
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S6">6</xref>
###xml 179 181 179 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 213 214 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 306 308 306 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 342 343 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 348 350 348 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 359 361 359 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Similarly, RP.1 cells sorted as 100% CD133+ cells exhibited decreased expression after two passages in monolayer (Additional file 6 [panel B]), whereas cells depleted of the CD133+ population (sorted as 100% CD133-) were unable to reconstitute the parental population and had a low fraction (0.6%) of CD133+ cells. These data reveal that CD44+/CD24- and CD133+ cells have similar capacity for self-renewal and repopulate cell fractions found in the respective parental cells.
###end p 48
###begin title 49
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
Brca1 cells have variable sensitivity to DNA damaging agents
###end title 49
###begin p 50
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 658 660 658 660 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 742 743 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
To establish the sensitivity of Brca1 cell lines to different drugs frequently used to treat breast cancer patients, cell lines were treated with different classes of DNA-damaging agents represented by doxorubicin, cisplatin, and etoposide. In addition, we used a novel orally available molecular targeted agent, namely 17-DMAG, which is a naturally occurring ansamycin antibiotics derived from geldanamycin (GA, NSC 122750). 17-DMAG was tested because it affects multiple targets and interferes with both cell survival and DNA repair pathways [20-24]. All cells were relatively similar in their response to cisplatin, with a 50% inhibitory concentration (IC50) of 3 to 8 mumol/l, and were variably sensitive to other agents (Additional file 7 and data not shown).
###end p 50
###begin title 51
Cells expressing stem cell markers and cells derived from spheroids are highly resistant to chemotherapeutic agents
###end title 51
###begin p 52
###xml 116 117 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 122 124 122 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 127 128 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 137 138 137 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 143 145 143 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 410 412 410 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 472 474 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 496 498 494 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 503 504 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 509 510 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 583 585 581 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 590 591 588 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 596 597 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 622 625 620 623 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 660 661 657 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 666 668 663 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 671 672 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 699 702 696 699 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 728 730 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 1035 1037 1030 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 1067 1069 1062 1064 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1123 1125 1118 1120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1406 1408 1401 1403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1417 1419 1412 1414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
We compared sensitivity to drugs of parental A1.8 cells, cells dissociated from spheroids, and cells sorted for CD44+/CD24- (SC+) or CD44-/CD24+ (SC-) populations plated immediately after sorting. Cells were treated side-by-side on the following day with increasing concentrations of cisplatin (Figure 3). Cells derived from spheroids were significantly more resistant to cisplatin than parental cells, with IC50s of 16.675 mumol/l and 4.274 mumol/l, respectively (Figure 3a). In addition, the SC- (CD44-/CD24+) population was significantly more sensitive than was the parental or SC+ (CD44+/CD24-) populations, with an IC50 of 1.384 mumol/l. Furthermore, CD44+/CD24- (SC+) cells had an estimated IC50 of 45.846 mumol/l (Figure 3b), as calculated using CalcuSyn Software. Because of gradual loss of stem cell markers in cells growing as a monolayer, these data may further underestimate chemoresistance of the cancer stem cells. The morphology of each cell fraction after 48 hours of exposure to 8 mumol/l cisplatin is shown in Figure 3c. Although the parental and SC- population exhibited significant signs of toxicity, SC+ cells have few signs of toxicity and cells dispersed from spheroids showed small aggregates, indicating a delay in cell growth, but remarkably there were no significant signs of toxicity. Similar results were obtained with parental RP.1 cells, spheroids, and cells sorted for CD133+ and CD133- populations (data not shown).
###end p 52
###begin p 53
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 198 199 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 204 205 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 234 235 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 331 335 331 335 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 424 428 424 428 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 521 525 521 525 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
Brca1 cells expressing stem cell markers and cells growing as spheroids are highly resistant to cisplatin. A1.8 parental cells, cells from dispersed spheroids, and cells sorted for Stem Cell + (CD44+/CD24-) and Stem Cell - (CD44-/CD24+) markers were treated simultaneously with increasing concentrations of cisplatin for 48 hours. (a) Parental A1.8 cells (solid symbols) compared with spheroid-derived cells (open symbols). (b) A1.8 cells sorted as Stem Cell + (open symbols) and Stem Cell - (solid symbols) populations. (c) Morphologic appearance of control untreated cells and cells exposed to 8 mumol/l cisplatin, as indicated on each panel. Note the formation of aggregates from spheroid-derived dispersed cells at the end of 72 hours in culture. One of three independent experiments is shown here.
###end p 53
###begin title 54
Cells sorted for cancer stem cell makers lose their drug resistance when grown in monolayers
###end title 54
###begin p 55
###xml 142 143 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 148 150 148 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 153 154 153 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 161 162 161 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 167 169 167 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 190 192 190 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 201 203 201 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
To determine whether cells sorted for putative cancer stem cell markers lose the drug resistance after growing in monolayers, sorted A1.8 CD44+/CD24- (SC+), CD44-/CD24+ (SC-), and RP.1 CD133+ and CD133- cells were passaged four times as monolayer. In addition to losing enrichment in stem cell markers, as described above, these cells lost differences in sensitivity to cisplatin as compared with parental cells (data not shown).
###end p 55
###begin title 56
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
Expression of multidrug resistance genes in Brca1 stem cells
###end title 56
###begin p 57
###xml 366 371 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pmca4</italic>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 534 540 534 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1a</italic>
###xml 542 548 542 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1b</italic>
###xml 550 555 550 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcc1</italic>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcg2</italic>
###xml 582 588 582 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcg2 </italic>
###xml 776 777 776 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S8">8</xref>
###xml 796 802 796 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcg2 </italic>
###xml 322 326 <span type="species:ncbi:10090">mice</span>
To determine whether drug resistance of cells expressing stem cell surface markers is due to expression of multidrug resistance genes, we compared expression of several selected ABC transporters in five cell lines representative from each primary tumor and compared their expression with normal mammary gland from C57/Bl6 mice. Data were normalized to expression of Pmca4, a housekeeping gene [19]. Using a panel of ABC transporters most likely to be responsible for drug resistance to the chemotherapeutic agents tested, we included Abcb1a, Abcb1b, Abcc1, and Abcg2. Expression of Abcg2 was higher in all cell lines except for P3.17. The highest level, with a 25-fold increase, was in B.15 cells, as compared with expression in normal mammary gland (C57/Bl6; Additional file 8 [panel A]). Thus, Abcg2 expression did not correlate with the presence of stem cell population or with the ability of cells to survive in the absence of attachment, because B15 cells were more sensitive to all drugs, lacked enrichment in stem cell markers, and did not form spheroids.
###end p 57
###begin p 58
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1b </italic>
###xml 27 30 27 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pgp</italic>
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mdr1</italic>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S8">8</xref>
Remarkably, higher Abcb1b (Pgp, Mdr1) expression, but not that of the other ABC transporters, was detected in cell lines enriched in cancer stem cell markers, namely A1.8 and RP.1 (Additional file 8 [panel B] and data not shown).
###end p 58
###begin p 59
###xml 199 205 199 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S8">8</xref>
###xml 254 260 254 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1b</italic>
###xml 359 365 359 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1 </italic>
###xml 432 434 432 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 471 473 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 570 572 570 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 670 671 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S8">8</xref>
We also compared expression of ABC transporters in parental cell lines, spheroids, and cells sorted for positive or negative stem cell markers, versus RNA levels in the respective original A1 and RP Brca1 tumors (Additional file 8 [panels C and D]). For Abcb1b, parental and sorted populations of A1.8 cells had a substantial fivefold to ninefold increase in Abcb1 expression, with the greatest increase in A1.8 parental and A1.8 SC+ sorted cells. In contrast, RP.1 CD133- and parental cells had a fivefold increase when compared with the primary RP tumor, whereas CD133+ cells and spheroids retained the expression level found in the original RP tumor (Additional file 8 [panel C]).
###end p 59
###begin p 60
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcg2 </italic>
###xml 47 48 47 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S8">8</xref>
###xml 102 104 102 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 133 135 133 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 159 161 159 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcg2</italic>
###xml 240 242 240 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1</italic>
###xml 409 414 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcg2</italic>
Analysis of Abcg2 transporter (Additional file 8 [panel D]) in A1.8 cells revealed higher levels in SC+ and parental cells than in SC- or spheroids. RP.1 CD133- cells showed the highest level of Abcg2, whereas RP.1 parental cell line, CD133+ fraction, and spheroids showed fivefold increase as compared with levels found in the original RP tumor. These data indicate that expression of Abcb1, but not that of Abcg2, correlates with drug resistance.
###end p 60
###begin title 61
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
17-DMAG sensitizes Brca1 cells to chemotherapeutic agents
###end title 61
###begin p 62
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 801 802 801 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1065 1067 1065 1067 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1183 1185 1183 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
We also examined whether the heat shock protein (HSP)90 inhibitor 17-DMAG sensitizes Brca1 cells to DNA-damaging agents and whether the schedule of administration plays a significant role. Doxorubicin, cisplatin, or etoposide were added simultaneously or sequentially, with 17-DMAG added 24 hours before or after DNA damaging agents. Calculation of Combination Index (CI) was modeled by CalcuSyn software to establish synergy or antagonism of the drug interaction. A CI of 1 indicates an additive effect whereas under 1 reflects a synergistic effect. For all cell lines and drugs tested, the combination therapy was synergistic and more effective than either drug alone, but no additional synergy was noted if 17-DMAG was added 24 hours after cisplatin as compared with simultaneous treatment (Figure 4). Similar results were obtained using doxorubicin and 17-DMAG (data not shown). In contrast, significant antagonism with CI above 1 was observed when cells were exposed to 17-DMAG before cisplatin (not shown). These data are consistent with previously reported G1 arrest induced by HSP90 inhibitors in other cancer cells, which makes them highly resistant to DNA-damaging agents [20].
###end p 62
###begin p 63
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 277 281 277 281 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 533 537 533 537 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 952 956 950 954 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 1320 1324 1318 1322 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
17-DMAG is synergistic with cisplatin for Brca1 parental and cancer stem cells. Cells were treated with increasing concentrations of cisplatin, 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), or a combination of both drugs at a constant 1:3 ratio. (a) Simultaneous treatment for 48 hours. The open circles and dotted lines represent exposure to 17-DMAG, the filled circles and dotted lines represent exposure to cisplatin as single agents, and the filled squares linked by a solid line show combination. (b) Sequential addition of the drugs. The filled circles show exposure for 48 hours to cisplatin, the open circles and dotted lines represent 24 hours pf exposure to 17-DMAG, and the filled squares linked by a solid line show combination. The ordinate indicates concentrations of cisplatin, and the error bars represent +/- standatd deviation from sextuplicates wells of one of more than three independent experiments. (c) Visual representation of Combination Index (CI) for each combination calculated using CalcuSyn Software. The closed circles represent simultaneous treatment and the open circles represent sequential addition of cisplatin followed by 17-DMAG. Values of CI below 1 indicate synergy, values above 1 represent antagonism, and CI = 1 corresponds to an additive effect. (d) 17-DMAG sensitizes parental and cancer stem cells to Cisplatin. CI for cisplatin and 17-DMAG added simultaneously (+) or sequentially (-->) to parental cells or cells sorted for putative cancer stem cell markers. Data are derived from more than three independent experiments.
###end p 63
###begin p 64
###xml 511 515 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c,d</xref>
We also examined whether the combination of cisplatin with 17-DMAG sensitizes the putative cancer stem cells to DNA-damaging agents. Cells from A1.8 and RP.1 parental cells sorted for respective stem cell positive and negative markers were exposed to cisplatin and 17-DMAG simultaneously or sequentially. Combination therapy was highly synergistic for all drug doses, with CI significantly below 1, regardless of simultaneous or sequential (with 17-DMAG added 24 hours later) schedule of administration (Figure 4c,d).
###end p 64
###begin title 65
Tumor-initiating capacity of cells bearing stem cell markers
###end title 65
###begin p 66
###xml 90 97 90 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 321 323 321 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 328 330 328 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 374 376 374 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 476 478 476 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 550 552 550 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 604 606 604 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 611 613 611 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 705 707 705 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 840 842 840 842 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1091 1093 1091 1093 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1154 1155 1154 1155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 349 353 <span type="species:ncbi:10090">mice</span>
###xml 805 810 <span type="species:ncbi:10090">mouse</span>
###xml 991 995 <span type="species:ncbi:10090">mice</span>
###xml 1058 1062 <span type="species:ncbi:10090">mice</span>
To determine whether cells that express distinct cancer stem cell markers are tumorigenic in vivo, increasing numbers of RP.1 (Figure 5a) and A1.8 (Figure 5b) cells sorted for expression of cancer stem cell markers were injected into mice, starting with 50 cells/injection. Only two out of three mice that received 5 x 103 CD133- RP.1 cells, and no mice injected with 1 x 103 cells or fewer formed tumors within 40 days (Figure 5a). In contrast, all cells sorted for the CD133+ marker were highly tumorigenic, with tumors formed by as few as 50 CD133+ cells. In addition, the tumors generated from 5 x 103 CD133+ cells were at least 10-fold larger that the tumors formed from the same cell number of CD133- cells at the end of 40 days. Animals having no tumors were observed for an additional 60 days. No mouse that received 50 or 100 CD133- cells formed tumors or exhibited evidence of small tumors after examination of the mammary gland after 60 days (not shown). Four of a total of eight mice that received 5,000 cells and an additional three out of nine mice that received 1,000 RP CD133- cells had small tumors, measuring on average less than 200 mm3, after 2 months.
###end p 66
###begin p 67
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 41 43 41 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 51 53 51 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 274 278 274 278 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 288 290 288 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 320 322 320 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 333 337 333 337 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 346 347 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 352 354 352 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 576 580 576 580 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 192 197 <span type="species:ncbi:10090">mouse</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 596 600 <span type="species:ncbi:10090">mice</span>
Cells sorted for expression of CD44+/CD24- or CD133+ markers are enriched in tumor-initiating cells. Tumor initiating capacity was determined by implantation of 50, 100, 500 or 1,000 cells in mouse fat pad (MFP) #4 of nonobese diabetic/severe combined immunodeficient mice. (a) RP.1 CD133+ cells compared with RP.1 CD133- cells, and (b) A1.8 CD44+/CD24- cells compared with parental cells. Tumor growth rates were monitored, as described in Materials and methods, and average tumor size is shown for each cell type and cell number implanted based on triplicate implantations. (c) Total number of mice that grew tumors, as determined from independent experiments performed for each cell line. The percentages of positive tumors are indicated in parentheses.
###end p 67
###begin p 68
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 86 88 86 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 359 361 359 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 374 375 374 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 380 382 380 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 427 435 427 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 491 497 491 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
Although tumors formed by A1.8 cells grew slower than did RP.1 tumors, A1.8 CD44+/CD24- cells were also highly enriched in tumor-initiating cells, and 50 to 100 cells were sufficient to generate tumors in 60 days (Figure 5b). Statistical analysis of multiple experiments conducted in these cells, summarized in Figure 5c, confirms the enrichment of RP.1 CD133+ and A1.8 CD44+/CD24- populations in tumor-initiating cells. These in vivo tumorigenesis studies for both cell types indicate that Brca1 cells bearing distinct cancer stem cell markers are enriched at least 50-fold to 100-fold in tumor-initiating cells.
###end p 68
###begin title 69
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
Molecular characterization of Brca1 cancer stem cells
###end title 69
###begin p 70
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 331 332 331 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 337 339 337 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 342 343 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 357 358 357 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 361 363 361 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 366 367 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 414 416 414 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 429 431 429 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 616 622 616 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch1</italic>
###xml 624 629 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr1</italic>
###xml 631 635 631 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD44</italic>
###xml 641 645 641 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox1</italic>
###xml 704 705 704 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 710 712 710 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 721 723 721 723 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 738 746 738 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aldh1a1 </italic>
###xml 848 850 848 850 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 871 873 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 961 966 961 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRT15</italic>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1055 1056 1055 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1062 1077 1062 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Desert hedgehog</italic>
###xml 1125 1127 1125 1127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1141 1143 1141 1143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1062 1077 <span type="species:ncbi:262775">Desert hedgehog</span>
To determine whether Brca1 cells that express putative stem cell markers express other genes that are characteristic of stem cells, we compared RNA levels of stem cell associated genes in cells sorted for positive and negative expression of stem cell markers. Of 84 genes from the SuperArray panel, 11 genes were higher in A.8 CD44+/CD24- (SC+) than in CD44-/24+ (SC-) cells, and 18 genes were higher in RP.1 CD133+ than in CD133- cells, as determined by real-time quantitative PCR (Table 1). There was a remarkable overlap among stem cell genes over-expressed in both cell types, with seven shared genes, including Notch1, Fgfr1, CD44, and Sox1. Other genes whose over-expression was common between CD44+/CD24- and CD133+ cells included Aldh1a1 (encoding aldehyde dehydrogenase), which was previously associated with hematopoietic, skin, and CD133+ neuronal stem cells [25]. Genes different between cancer stem cell populations in A1.8 and RP.1 cells included KRT15, a marker of basal breast cancer type [26], with 17-fold higher expression in RP.1 CD133+, and Desert hedgehog, with 4.3-fold higher expression in the A1.8 SC+ than in the SC- population.
###end p 70
###begin p 71
Expression of stem cell genes in cells that express stem cell markers
###end p 71
###begin p 72
Expression of genes from a panel of 84 stem cell-associated genes was determined by SuperArray real-time PCR using RNA from A1.8 and RP.1 cells sorted for CD44, CD24, or CD133 markers (SC+ and SC-). For a complete list of genes tested, see [48]. The results are expressed as fold increase in cells sorted positive over negative markers from replicate experiments. Data are normalized to five housekeeping genes, as per the manufacturers' instructions. Genes common for both cell lines are presented at the top.
###end p 72
###begin p 73
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
To validate our gene expression findings and to define further the two types of cancer stem cells, we conducted immunofluorescence studies on spheroids derived from A1.8 and RP.1 cells using antibodies to common and unique stem cell associated gene products. As seen in Figure 6, spheroids from both cell lines were positive for Oct4, a common key marker of pluripotency. CD133 and Numb, a marker associated with asymmetric division, were present in RP.1 but not in A1.8 spheroids, which confirmed the data obtained by real-time quantitative PCR described above, and both were negative for Nestin, which is a marker of early neuronal differentiation (data not shown). These data suggest that, in spite of having distinct and nonoverlapping cell surface makers, the A1.8 and RP.1 cells have significant similarities in expression of stem cell genes.
###end p 73
###begin p 74
Cells growing as spheroids express stem cell proteins. Immunofluorescence of spheroids formed by A1.8 and RP.1 cells after four passages were stained for Numb, Oct4, and CD133. Cells growing as spheroids were allowed to attach to an eight-well slide, fixed, and stained with indicated antibodies. Staining for Oct4 is visualized in both cell lines, whereas expression of Numb and CD1333 is evident only in RP.1 cells.
###end p 74
###begin p 75
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S9">9</xref>
###xml 510 516 510 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
We also examined the expression of estrogen receptor 1 in tumors and cell lines and compared it with expression in normal C57BL6 mice virgin mammary gland. The primary tumors and corresponding cell lines exhibited lower estrogen receptor 1 expression, with threefold to fivefold lower expression in A.8 and RP.1, and 22-fold decrease in B.15 cells (Additional file 9 and data not shown). These data are consistent with a previously published report of decreased estrogen receptor expression in fully developed Brca1 tumors [27].
###end p 75
###begin title 76
Discussion
###end title 76
###begin p 77
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 154 156 154 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 165 166 165 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 339 348 339 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 819 824 819 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 854 855 854 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 860 866 860 866 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/Low </sup>
###xml 932 934 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 935 937 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 971 973 971 973 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1030 1032 1030 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
###xml 702 707 <span type="species:ncbi:10090">mouse</span>
###xml 900 905 <span type="species:ncbi:9606">human</span>
###xml 1083 1088 <span type="species:ncbi:9606">human</span>
Cell lines derived from individual Brca1 mouse mammary tumors had distinct and non-overlapping populations of putative cancer stem cell markers CD44+/CD24- and CD133+. Only cell lines that contained a significant fraction of cells with these markers formed spheroid structures without preliminary sorting, and expansion of these spheroids in vitro led to further spontaneous enrichment in cells with stem cell makers. In addition, cells sorted for cancer stem cell markers and cells growing as spheroids were significantly more resistant to chemotherapeutic agents than were parental cells, and were highly tumorigenic in mice. Two conclusions can be derived from these studies. First, Brca1-deficient mouse mammary tumors contain heterogeneous populations of cells that share cancer stem cell properties. Second, some Brca1-deficient tumors contain CD44+/CD24-/Low cells, previously associated with human breast cancer stem cells [10,11,28], whereas others contain CD133+ cells previously associated with tumors in other organs [29]. Which population provides a closer correlate to human disease requires further study.
###end p 77
###begin p 78
###xml 225 233 225 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 403 411 403 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 549 557 549 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 747 756 747 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 858 867 858 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 10 16 <span type="species:ncbi:10090">murine</span>
Human and murine cancer cell lines contain a small fraction of cells that have cancer stem cell properties. These cells are drug resistant, express stem cell associated genes, and have high capacity for reconstituting tumors in vivo [9,28,30,31]. Because they constitute a very small cell fraction, their characterization requires isolation, usually by sorting based cell surface markers, and expansion in vitro. Our data confirm that cells sorted for cancer stem cell markers reconstitute the parental population after a limited number of passages in vitro. Repopulation is indicative of self-renewal, presumably by asymmetric division, and is consistent with stem cell-like properties of these cells. However, the expansion of sorted stem cells in vitro results in rapid reduction in the cell fraction that expresses stem cell phenotype, which complicates in vitro studies of cancer stem cell biology and development of specific therapies.
###end p 78
###begin p 79
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 769 775 769 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 1040 1048 1040 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Other investigators have reported that cancer-initiating cells sorted from established cell lines or primary tumors form spheroids when plated in semisolid support or serum-free media supplemented with epidermal grwoth factor and basic fibroblast growth factor [9]. Breast cancer-derived spheroid structures have been termed mammospheres and have similarities to those derived from normal mammary glands. Neurospheres derived from neural tissues or gliomas grow in similar conditions [32]. Brca1 tumor cells sorted for expression of putative stem cell markers formed spheroids in the absence of attachment without supplementation with growth factors. Furthermore, neither sorting nor growth factor supplementation was required for generation of spheroids from unsorted Brca1 cell lines that had a substantial population of cells expressing stem cell markers. The unsorted cells that grew spheroids in long-term culture were significantly enriched in stem cell makers and were highly resistant to DNA-damaging agents after multiple passages in vitro. Whether other cancer cells that ordinarily grow in monolayer can survive in the absence of attachment and form spheroids, and become enriched in cancer stem cells remains to be established.
###end p 79
###begin p 80
###xml 389 395 389 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 584 589 584 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 788 793 <span type="species:ncbi:9606">human</span>
In contrast to the orderly transition of normal stem cells through differentiation with generation of progenitor and terminally differentiated cells, multistep carcinogenesis is likely to generate heterogeneity in cancer-initiating population, which is reflected in different cell surface markers that identify cancer stem cells in different tumor types. Previous studies corroborate that BRCA1 deficiency results in genetic instability associated with centrosome amplification, defective cell cycle checkpoint control, and impaired DNA damage repair [33,34]. We found that that same Brca1-deficient genetic background gave rise to mammary tumors with two distinct and non-overlapping populations of cells that bear cell surface markers previously assigned to tumor-initiating cells from human breast and other organs. Differences in cancer stem cell populations, which constitute a minute fraction of total tumor, may underlie some of the difficulties in using the genome-wide approach to characterizing molecular profiles for these tumors.
###end p 80
###begin p 81
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 43 49 43 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/Low </sup>
###xml 126 135 126 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 151 158 151 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 334 335 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 340 342 340 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 422 430 422 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 49 54 <span type="species:ncbi:9606">human</span>
###xml 358 363 <span type="species:ncbi:10090">mouse</span>
###xml 491 495 <span type="species:ncbi:10090">mice</span>
Previous studies showed that 200 CD44+/CD24-/Low human breast cancer cells reconstitute the entire population of cancer cells in vitro and form tumors in vivo, whereas larger numbers of parental cells or cells sorted for the absence of these markers are needed to generate smaller, slower growing tumors [10,11,28]. We found that CD44+/CD24- Brca1-deficient mouse mammary tumor cells have cancer stem cell characteristics in vitro, and 50 of these cells are sufficient to initiate tumors in mice.
###end p 81
###begin p 82
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 441 446 <span type="species:ncbi:9606">human</span>
CD44 is a complex, multispanning, transmembrane glycoprotein whose expression correlates with drug resistance and poor prognosis in many malignancies [35]. In addition to hyaluronic acid, CD44 binds fibrinogen, fibronectin, collagen, laminin, fibroblast growth factor-2, other heparin-binding growth factors, and osteopontin, an inflammatory cytokine that is associated with metastatic progression. Recent reports suggested heterogeneity in human breast cancer stem cells that express CD44 [36,37]. Whether CD44 expression plays a direct role in drug resistance by activating multiple survival pathways via growth factor receptors or integrin-mediated 'inside-out' signaling is not known and warrants further investigation.
###end p 82
###begin p 83
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 203 207 203 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low </sup>
###xml 318 320 318 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 551 553 551 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 642 644 642 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 855 857 855 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 919 924 919 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 149 154 <span type="species:ncbi:10090">mouse</span>
###xml 174 180 <span type="species:ncbi:10090">murine</span>
###xml 791 796 <span type="species:ncbi:10090">mouse</span>
Although expression of CD24 negatively correlated with stem cell characteristics in human breast cancer [10,11,28], the situation is more complex in mouse mammary tumors. In murine mammary gland the CD24low cells correspond to myoepithelial cells and have high mammary fat pad reconstitution capacity, whereas the CD24+ population has low capacity for reconstitution and is devoid of normal mammary stem cells [34]. Furthermore, Weinberg and colleagues [39] recently reported that mammosphere-forming and tumor-initiating capacities reside within CD24+ freshly isolated normal mammary cells, but when these cells are briefly cultured the CD24- population was enriched with cancer stem cells. These previously reported differences in expression of CD24 in different tumor types and in normal mouse mammary epithelium support our search for the role of CD24- cells in combination with a more established marker, CD44, in BRCA1-deficient tumors.
###end p 83
###begin p 84
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 184 186 184 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 232 238 232 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 295 296 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 301 303 301 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 403 405 403 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 447 455 447 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 957 959 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
Expression of CD133 in cancer-initiating cells is well documented for brain, prostate, and colon cancers [29] but has not been described in breast cancer. We detected 2% to 4% of CD133+ cells in multiple cell lines derived from one Brca1 tumor with characteristics similar to those found in CD44+/CD24- cells, including drug resistance, the ability to form spheroids with further 30% enrichment in CD133+ cells, expression of stem cell genes, and in vivo reconstitution of tumors with as few as 100 cells. CD133, also known as prominin-1, is a cell-surface glycoprotein with five transmembrane domains and two large glycosylated extracellular loops that localize to membrane protrusions [29]. The function of CD133 in cancer stem cells has not been established, but one alternatively spliced form binds cholesterol and thus may be involved in Hedgehog signaling, which is required for primitive cell differentiation and epithelial-mesenchymal interactions [40].
###end p 84
###begin p 85
###xml 184 192 184 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 237 243 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 288 296 288 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 670 676 670 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 104 109 <span type="species:ncbi:10090">mouse</span>
###xml 526 530 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 540 544 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 579 584 <span type="species:ncbi:10090">mouse</span>
We previously described generation of tumors from cell suspensions from multiple genetically engineered mouse mammary tumors and their expansion by transplantation in naive recipients in vivo [16]. Gene expression analysis of individual Brca1 mammary tumors and their subsequent passages in vivo revealed substantial heterogeneity in gene expression [40], as predicted by differences in frequency and identity of cancer stem cell populations in cell lines derived from these tumors. Thus, in contrast to other models, such as MMTV-PyMT and MMTV-wnt1, in which pooling individual mouse tumors can generate sufficient material for basic and translational studies [16,42], Brca1 tumors will need to be analyzed individually and these studies are limited by the size of each original tumor. Thus, generation of cell lines provided valuable reagents for these studies.
###end p 85
###begin p 86
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 613 614 613 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 619 621 619 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 644 646 644 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 173 178 <span type="species:ncbi:9606">human</span>
A fundamental characteristic of cancer stem cells is their resistance to chemotherapeutic agents. Much understanding of BRCA1 drug resistance comes from studies of a single human cell line, namely H1937, which is null for the BRCA1 gene. Although replacement of this gene increases resistance to vinorelbine and cisplatin, it does not change sensitivity to other agents, such as docetaxel [43,44]. This suggests that other mechanisms may determine drug resistance in that cell line. Consistent with these observations, we found that H1937 cells contain a significant (2% to 3%) population of cells expressing CD44+/CD24- and no detectable CD133+ (data not shown). The contribution of these cells to drug sensitivity remains to be determined.
###end p 86
###begin p 87
###xml 105 112 105 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1b </italic>
###xml 228 235 228 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1b </italic>
###xml 355 357 355 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 377 379 377 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 418 424 418 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1b</italic>
###xml 436 442 436 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcg2 </italic>
###xml 519 525 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 642 648 642 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcg2 </italic>
###xml 903 904 903 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 909 911 909 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 920 922 920 922 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 956 962 956 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 1050 1056 1050 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans </italic>
###xml 1153 1155 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
Over-expression of several ABC transporters has been linked to drug resistance. Our analysis showed that Abcb1b expression correlated with an increase in cells having stem cell markers in A1.8 and RP.1 cell lines. Expression of Abcb1b was further enriched in A.8 cells sorted for stem cell markers. However, this did not occur in RP.1 cells, because CD133- cells, but not CD133+ cells, exhibited greater expression of Abcb1b. Increased Abcg2 expression, previously associated with cancer stem cells, was evident in all Brca1 cell lines, regardless of presence or absence of putative stem cell fraction. Furthermore, the highest expression of Abcg2 was detected in B.15, a cell line that was not enriched in stem cell markers and did not form spheroids. Thus, expression of other transporters, or different drug resistance mechanisms, such as aldehyde dehydrogenase, which was over-expressed in both CD44+/CD24- and CD133+ cell types, may be operational in Brca1 cancer stem cells. Aldehyde dehydrogenase-1 participates in oxidation of retinol to all-trans retinoic acid, and confers drug resistance to chemotherapeutic agents by an uncertain mechanism [45].
###end p 87
###begin p 88
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 511 517 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 788 796 788 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 853 859 853 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
We previously demonstrated schedule-dependent synergy of the HSP90 inhibitor 17-DMAG with doxorubicin for lymphoma cells [20]. Here, we found that addition of 17-DMAG simultaneously or after chemotherapeutic agents sensitizes Brca1 cancer stem cells to three types of DNA-damaging agents: doxorubicin, cisplatin, and etoposide. Because HSP90 inhibitors impair multiple signal transduction pathways, resulting in decreased cell survival and DNA repair [20,24,46], our data showed that functional inactivation of Brca1 is particularly vulnerable to this combination. Whether HSP90 inhibitors sensitize other cancer stem cells to chemotherapeutic agents remains to be established. Development of cancer stem cell-directed therapies has been hampered by inability to expand cancer stem cells in vitro. Enrichment of cancer stem cells in spheroids formed by Brca1 cell lines provides ample material for studies of cancer stem cell biology and preclinical testing.
###end p 88
###begin title 89
Conclusion
###end title 89
###begin p 90
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 102 104 102 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 16 21 <span type="species:ncbi:10090">mouse</span>
###xml 124 129 <span type="species:ncbi:9606">human</span>
Brca1-deficient mouse mammary tumors harbor heterogeneous cancer stem cell populations, and CD44+/CD24- cells also identify human breast cancer stem cells. In addition, long-term spheroid-forming assay may allow rapid screening of tumors for enrichment in cancer stem cells, identification of additional stem cell markers, and development of potentially curative therapies that target the putative cancer stem cell.
###end p 90
###begin title 91
Abbreviations
###end title 91
###begin p 92
###xml 131 134 131 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 281 282 281 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 166 170 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 173 198 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
ABC = ATP-binding cassette; CI = Combination Index; 17-DMAG = 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride; IC50 = 50% inhibitory concentration; MMTV = mouse mammary tumor virus; MTS = 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; PBS = phosphate-buffered saline; RT-PCR = reverse transcription polymerase chain reaction.
###end p 92
###begin title 93
Competing interests
###end title 93
###begin p 94
The authors declare that they have no competing interests.
###end p 94
###begin title 95
Authors' contributions
###end title 95
###begin p 96
###xml 126 134 126 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 249 257 249 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 515 523 515 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 273 278 <span type="species:ncbi:10090">mouse</span>
MHW developed all cell lines, and performed the flow cytometry labeling, RNA extraction and analysis, as well as drug testing in vitro. AMC performed all studies on expression of ABC transporters. CDS performed additional cell labeling, some of the in vivo injections into mouse fat pad, and tumor measurements. MDC performed tumor measurements and tumor dissections. SVA advised on testing and data interpretation for ABC transporter expression and other drug resistance mechanisms. LV performed tumor dissection, in vivo injections of cells into mammary fat pad, overall coordination, and design of the study.
###end p 96
###begin title 97
Supplementary Material
###end title 97
###begin title 98
Additional file 1
###end title 98
###begin p 99
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
File providing a list of oligonucleotide primer sequences for the mouse ABC transporters and plasma membrane calcium ATPase 4 (housekeeping gene) for quantitative real-time RT-PCR.
###end p 99
###begin p 100
Click here for file
###end p 100
###begin title 101
Additional file 2
###end title 101
###begin p 102
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
File showing the morphologic appearance of all 16 cell lines developed from five original independent Brca1 mammary tumors (A1, B, P3, P2, and RP) grown in monolayer.
###end p 102
###begin p 103
Click here for file
###end p 103
###begin title 104
Additional file 3
###end title 104
###begin p 105
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 70 72 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 81 82 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
File showing that expression of putative stem cell markers (CD44+/CD24- and CD133+) occurs on distinct and non-overlapping cell populations. (A) A1.8 cells stained simultaneously with antibodies for CD44, CD24, and CD133 (upper panel). The lower panel shows compensated dual staining for CD44/CD133, CD44/CD24, and triple staining for all three markers. Only 0.02% of A1.8 cells express all 3 markers. (B) RP.1 cells were stained and analyzed as above. No cells bearing all three markers are detectable. One of two independent analyses is shown here.
###end p 105
###begin p 106
Click here for file
###end p 106
###begin title 107
Additional file 4
###end title 107
###begin p 108
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 203 212 203 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 324 326 324 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 384 389 384 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
File showing that RP.1 cells growing as spheroids in the absence of attachment are enriched in CD133+ cells. (A) Parental cells and (B) cells dissociated from spheroids after expanding for four passages in vitro were stained side-by-side for CD133 and examined by fluorescence-activated cell sorting. The percentage of CD133+ cells is indicated in each box. Note that a distinct CD133High population is now evident in spheroid-derived cells. One of three independent experiments is shown here.
###end p 108
###begin p 109
Click here for file
###end p 109
###begin title 110
Additional file 5
###end title 110
###begin p 111
File showing the morphologic appearance of unsorted cells plated in the absence of attachment from six cell lines that represent five individual tumors. A1.1, A1.8, B.15, P3.17, P2.1, and RP.1 cells were grown in 96-well low-binding plates for 2 weeks, dispersed into single cells, and expanded in six-well low-binding plates. One of more than three independent experiments is shown here.
###end p 111
###begin p 112
Click here for file
###end p 112
###begin title 113
Additional file 6
###end title 113
###begin p 114
###xml 262 264 262 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 275 276 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 284 286 284 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 291 292 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 297 298 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 404 406 404 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 415 417 415 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
File showing differences in frequency of CD44/CD24 cells in A1.8 cell line that were growing in monolayer as compared to spheroids. (A) Fluorescence-activated cell sorting (FACS) analysis of stem cell markers from unsorted A1.8 parental cells is compared with SC+ (CD44+/CD24-) and SC- (CD44-/CD24+) cells sorted by FACS after growing as monolayers in the third passage (P.3). (B) RP.1 parental and CD133+ and CD133- cells sorted and passaged as monolayer twice (P.2) before analysis. One of three independent experiments is shown.
###end p 114
###begin p 115
Click here for file
###end p 115
###begin title 116
Additional file 7
###end title 116
###begin p 117
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
File showing the sensitivity of Brca1 cell lines to doxorubicin, cisplatin, and the HSP90 inhibitor 17-DMAG. Cytotoxicity is determined by MTS assay for four representative Brca1 cell lines: A1.8, P3.17, B.15, and RP.1. Cells were exposed to increasing concentrations of (A) doxorubicin, (B) cisplatin, and (C) the HSP90 inhibitor 17-DMAG. Percentage survival (+/- standard deviation from six replicate wells) after 24 hours of exposure to drugs is represented by open symbols and dotted lines, and after 48 hours by solid symbols and lines. The ordinate shows concentrations of individual drugs. One of three independent experiments for each cell type is shown here.
###end p 117
###begin p 118
Click here for file
###end p 118
###begin title 119
Additional file 8
###end title 119
###begin p 120
###xml 64 70 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcg2 </italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1</italic>
###xml 150 156 150 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcg2 </italic>
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1 </italic>
###xml 296 302 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcb1 </italic>
###xml 310 316 310 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abcg2 </italic>
###xml 482 488 482 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pmca4 </italic>
File showing the differences in expression of ABC transporters, Abcg2 and Abcb1, detected among the cell lines and parental tumors. (A) Expression of Abcg2 among six Brca1 cell lines. (B) Expression of Abcb1 in five cell lines that represent each one of the five independent tumors. Relative (C) Abcb1 and (D) Abcg2 expression in parental cells, cells sorted for respective stem cell markers, and unsorted cells growing as spheroids. Expression of each transporter is normalized to Pmca4 housekeeping gene, as described in Materials and methods. The bars represent +/- standard deviation from triplicate samples. One of three independent experiments is shown.
###end p 120
###begin p 121
Click here for file
###end p 121
###begin title 122
Additional file 9
###end title 122
###begin p 123
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
File showing estrogen receptor (ESR)1 expression in individual cell lines and normal mouse mammary gland from 8-week-old C57BL6 mice, as determined by quantitative RT-PCR. The data were calculated using the DeltaDeltaCT method from duplicate samples, in which the expression in each sample run was compared with expression in mammary gland, averaged, and normalized to cyclophilin, which was used as a housekeeping gene.
###end p 123
###begin p 124
Click here for file
###end p 124
###begin title 125
Acknowledgements
###end title 125
###begin p 126
The authors wish to thank Curtis C Harris for support, Barbara Taylor for assistance with flow cytometry, Ana Robles for molecular analysis, Irwin M Arias for critical review of the manuscript, and Karen MacPherson for editorial assistance. This work was supported by the Center for Cancer Research intramural program at the National Cancer Institute, Bethesda, MD, USA.
###end p 126
###begin article-title 127
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
###end article-title 127
###begin article-title 128
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
###end article-title 128
###begin article-title 129
BRCA1 mutations in primary breast and ovarian carcinomas
###end article-title 129
###begin article-title 130
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Mutations in the BRCA1 gene in Japanese breast cancer patients
###end article-title 130
###begin article-title 131
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors
###end article-title 131
###begin article-title 132
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics
###end article-title 132
###begin article-title 133
Relevance of DNA methylation in the management of cancer
###end article-title 133
###begin article-title 134
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
###end article-title 134
###begin article-title 135
Cancer stem cells: an old idea that's new again: implications for the diagnosis and treatment of breast cancer
###end article-title 135
###begin article-title 136
A self-renewal assay for cancer stem cells
###end article-title 136
###begin article-title 137
Prospective identification of tumorigenic breast cancer cells
###end article-title 137
###begin article-title 138
Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells
###end article-title 138
###begin article-title 139
###xml 65 69 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 76 82 <span type="species:ncbi:10090">murine</span>
Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors
###end article-title 139
###begin article-title 140
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects
###end article-title 140
###begin article-title 141
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis
###end article-title 141
###begin article-title 142
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models
###end article-title 142
###begin article-title 143
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
###end article-title 143
###begin article-title 144
Protocols for screening chemical agents and natural products agains animal tumors and other biological systems
###end article-title 144
###begin article-title 145
Plasma membrane calcium ATPase (PMCA4): a housekeeper for RT-PCR relative quantification of polytopic membrane proteins
###end article-title 145
###begin article-title 146
Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines
###end article-title 146
###begin article-title 147
In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative
###end article-title 147
###begin article-title 148
Discovery and development of pyrazole-scaffold Hsp90 inhibitors
###end article-title 148
###begin article-title 149
Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
###end article-title 149
###begin article-title 150
HSP90 inhibitor, 17-DMAG, radiosensitizes lung cancer cells by blocking DNA repair regardless of p53 status
###end article-title 150
###begin article-title 151
###xml 100 105 <span type="species:ncbi:9606">human</span>
Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells
###end article-title 151
###begin article-title 152
###xml 61 67 <span type="species:ncbi:10090">murine</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
###end article-title 152
###begin article-title 153
A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation
###end article-title 153
###begin article-title 154
###xml 18 24 <span type="species:ncbi:10090">murine</span>
Identification of murine mammary stem cells: implications for studies of mammary development and carcinogenesis
###end article-title 154
###begin article-title 155
Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?
###end article-title 155
###begin article-title 156
###xml 37 40 <span type="species:ncbi:10116">rat</span>
Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells
###end article-title 156
###begin article-title 157
Opinion: the origin of the cancer stem cell: current controversies and new insights
###end article-title 157
###begin article-title 158
Isolation of neural stem cells from the postnatal cerebellum
###end article-title 158
###begin article-title 159
The role of the BRCA1 tumor suppressor in DNA double-strand break repair
###end article-title 159
###begin article-title 160
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution
###end article-title 160
###begin article-title 161
CD44 in cancer
###end article-title 161
###begin article-title 162
Molecular definition of breast tumor heterogeneity
###end article-title 162
###begin article-title 163
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
Steroid hormone receptor status of mouse mammary stem cells
###end article-title 163
###begin article-title 164
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells
###end article-title 164
###begin article-title 165
Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity
###end article-title 165
###begin article-title 166
The hedgehog signaling pathway in cancer
###end article-title 166
###begin article-title 167
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for BRCA1
###end article-title 167
###begin article-title 168
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
Harnessing genetically engineered mouse models for preclinical testing
###end article-title 168
###begin article-title 169
###xml 50 55 <span type="species:ncbi:9606">human</span>
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents
###end article-title 169
###begin article-title 170
###xml 79 84 <span type="species:ncbi:9606">human</span>
RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells
###end article-title 170
###begin article-title 171
New perspectives for cancer chemotherapy by genetic protection of haematopoietic cells
###end article-title 171
###begin article-title 172
Inhibition of hsp90 compromises the DNA damage response to radiation
###end article-title 172
###begin article-title 173
HSP90 inhibitor, 17-DMAG, radiosensitizes lung cancer cells by blocking DNA repair regardless of p53 status
###end article-title 173
###begin article-title 174
###xml 2 4 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
RT2 Profilertrade mark PCR Array System Application Example
###end article-title 174

